Stay updated on Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to reflect a new version of a clinical study on esophageal squamous cell carcinoma, with changes in the study's revision number and the principal investigator's name. Additionally, some detailed eligibility criteria and study descriptions have been removed.SummaryDifference46%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4 and removed a date reference of March 25, 2025, while adding a new date of December 19, 2024.SummaryDifference0.8%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in Esophageal Cancer Clinical Trial page.